Severe Ketoacidosis as the First Clinical Manifestation of Type 1 Diabetes Mellitus Secondary to Immune Checkpoint Inhibitors

Severe Ketoacidosis as the First Clinical Manifestation of Type 1 Diabetes Mellitus Secondary to Immune Checkpoint Inhibitors

Introduction Immunotherapy represents one of the fundamental points on the oncological treatments. The increasingly frequent use of these treatments has allowed us to observe various side effects in up to 10 to 20% of patients and endocrine side effects are one of the most commonly described. We rep...

Full description

Bibliographic Details
Main Authors: Alejandro Olivares-Hernández, Roberto A. Escala-Cornejo, Araceli R. García-Domínguez, Juan J. Cruz-Hernández
Format: Article
Language:English
Published: Thieme Medical Publishers, Inc. 2020-04-01
Series:Asian Journal of Oncology
Subjects:
c-peptide
immunotherapy
ketoacidosis
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1710147

Similar Items

Similar Items